News - Anti-Arthritics/Rheumatics, Markets & Marketing


Popular Filters

1 to 25 of 55 results

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA


Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Prasco to market the authorized generic of Lilly’s Evista in USA


Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly to market…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsMarkets & MarketingNorth AmericaPrasco LaboratoriesUSA

Pipeline innovation bodes well for systemic lupus erythematosus market


While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Biologics reimbursement trends in Argentina, Brazil and Mexico

Biologics reimbursement trends in Argentina, Brazil and Mexico


Novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently…

Anti-Arthritics/RheumaticsArgentinaBiotechnologyBrazilMalaysiaMarkets & MarketingOncologyPricingSouth America

Rapid uptake of rheumatoid arthritis biosimilars expected in Brazil and Mexico


Biosimilars will be quickly acquired and used in public health institutions in the treatment of patients…

Anti-Arthritics/RheumaticsBiosimilarsBrazilGenericsMarkets & MarketingRegulationSouth America

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler


French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe

Biogen Idec and Samsung Bioepis to market anti-TNF biosimilars in Europe


US biotech major Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF…

Anti-Arthritics/RheumaticsBiogen IdecBiosimilarsBiotechnologyEuropeMarkets & MarketingSamsung Bioepis

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond


Key clinical, corporate and regulatory events affecting the biosimilar industry have been identified…

Anti-Arthritics/RheumaticsBiosimilarsCellTrionEuropeGenericsHospiraInflammatory diseasesInflectraMarkets & MarketingRegulationRemsima

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA


Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA


The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

EU5 rheumatologits rate Rituxan and Benlysta for Lupus


Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats


An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis


The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Japanese launches of subcutaneous injection forms of Pralia and Enbrel, and of Acofide


Among a bunch of Japanese drug launches in the past couple of days, Daiichi Sankyo (TYO: 4568) announced…

AcofideAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaDaiichi SankyodenosumabEnbrelGastro-intestinalsMarkets & MarketingPfizerPharmaceuticalPraliaTakeda PharmaceuticalsZeria Pharmaceuticals

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments


Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar


USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

Thought leader views on new osteoporosis and osteopenia treatments


US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is…

AMG-785AmgenAnti-Arthritics/RheumaticsBiotechnologyCDP-7851Eli LillyEuropeHealthcareMarkets & MarketingMerck & CoNorth AmericaodanacatibPharmaceuticalteriparatideUCB

Dr Reddy's launches first generic fondaparinux outside USA; debuts Reclast copy in USA


Australian drug developer Alchemia (ASX: ACL) says its commercialization partner, India's Dr Reddy's…

AlchemiaAnti-Arthritics/RheumaticsArixtraAsia-PacificCardio-vascularDr Reddy's LaboratoriesfondaparinuxGenericsGlaxoSmithKlineMarkets & MarketingNorth AmericaNovartisReclastzoledronic acid

Switch to anabolics driving osteoporosis market growth


A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

SOBI links with Savient for co-promotion of Kineret in USA


Swedish Orphan Biovitrum (STO: SOBI) says it has entered into an agreement with USA-based Savient Pharmaceuticals…

Anti-Arthritics/RheumaticsInflammatory diseasesKineretLicensingMarkets & MarketingNorth AmericaPharmaceuticalSavient PharmaceuticalsSobiSwedish Orphan Biovitrum

Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?


Since 2004, the market for monoclonal antibodies (MAbs) in rheumatoid arthritis (RA) has experienced…

Anti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingPharmaceuticalRemicade

Monoclonal antibodies market dominated by Remicade and Avastin


With the rollout of at least eight new therapeutic monoclonal antibody products and expanded indications…

Anti-Arthritics/RheumaticsBiotechnologyMarkets & MarketingOncology

1 to 25 of 55 results

Back to top